| crenolanib (ARO-002) / AROG |
NCT03116477: Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML |
|
|
| Not yet recruiting | 3 | 320 | NA | Crenolanib besylate, Cytarabine, Mitoxantrone, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Acute Myeloid Leukemia, in Relapse | 08/20 | 08/20 | | |
| Active, not recruiting | 3 | 120 | Europe, US | Crenolanib, Crenolanib Besylate, Placebo | Arog Pharmaceuticals, Inc., Centre Leon Berard, Fox Chase Cancer Center | GIST With D842V Mutated PDGFRA Gene | 08/21 | 08/21 | | |
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML |
|
|
| Recruiting | 3 | 510 | US | Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin | Arog Pharmaceuticals, Inc. | Newly Diagnosed FLT3 Mutated AML | 11/22 | 11/24 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
NCT02400255: Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients |
|
|
| Completed | 2 | 30 | US | Crenolanib besylate, CP-868,596-26 | Arog Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 05/22 | 05/22 | | |
NCT03620318: Individual Patient Compassionate Use of Crenolanib |
|
|
| Available | N/A | | Europe | Crenolanib besylate | Arog Pharmaceuticals, Inc. | FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification | | | | |